A Phase I/II Randomized, Double-blind, Placebo-controlled Trial (1-BETTER) Examining XB2001 (Anti-IL-1⍺ True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
Latest Information Update: 07 Aug 2026
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Vilamakitug (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms 1-BETTER
- Sponsors XBiotech
Most Recent Events
- 04 Aug 2026 Status changed from active, no longer recruiting to completed.
- 28 Feb 2025 Planned End Date changed from 10 May 2024 to 10 Jun 2025.
- 28 Feb 2025 Status changed from completed to active, no longer recruiting.